reptides › focus › NAD+

NAD+

not a peptide. the cofactor your mitochondria run on. IV drips are the longevity-clinic staple despite thin clinical evidence.

tier B · focus

verdict

not a peptide. the cofactor your mitochondria run on. the IV drip is the longevity-clinic staple; the oral precursors have most of the actual evidence.

if you're asking IV NAD+ vs oral precursors (NMN, NR) — oral NMN and NR at 250-1000 mg daily reliably elevate circulating NAD+. that's where most of the controlled trial evidence sits, plus modest improvements in insulin sensitivity, muscle function, and aerobic capacity. IV NAD+ at 250-1000 mg per session is the format clinics charge $300-1000 for. it has almost no rigorous controlled trials. a 2026 retrospective tolerability comparison (Frontiers in Aging) found IV NAD+ produced an inflammatory response that IV nicotinamide riboside did not.

if you're asking what the data actually shows — yes for raising blood NAD+ via oral precursors. uncertain for everything that comes after. the underlying biology is real. NAD+ decline with age is established across skin, muscle, liver, and blood. healthspan or lifespan extension in humans has not been demonstrated. the 2025 MIB-626 trial in COVID/AKI confirmed safe NAD+ elevation but no improvement on AKI markers. biomarker movement without outcome movement is the recurring pattern.

if you came in via the longevity-clinic IV drip pricing — the wellness industry built a multi-billion-dollar IV ecosystem around the biology, not around the IV evidence. NAD+ has more real biology than most longevity peptides and still nowhere near the clinical evidence the IV pricing implies. cheaper oral precursors carry most of the positive evidence.

based on published evidence and disclosed clinical practice. not medical advice.

why B-tier

B-tier because NAD+ and its precursors sit in a commercially mature but clinically ambiguous zone. The biology is real and well-established, NAD+ declines with age, precursor supplementation elevates levels, and some metabolic improvements are documented. The gap is between basic biology (strong) and clinical outcome evidence in humans (modest). B-tier also reflects that NAD+ itself isn't strictly a peptide, though it lives in the same clinical and commercial ecosystem. Could move to A-tier if the current wave of oral precursor trials delivers clear healthspan outcomes. Could drop to C-tier if the longevity hypothesis continues to fail to translate.

the core tension

NAD+ (nicotinamide adenine dinucleotide) is the most commercially successful 'longevity' compound of the last decade, but most of that commercial success runs on oral precursors like NMN and NR, not IV NAD+ itself. The precursor supplement evidence is substantial. The IV infusion evidence is much thinner, used in thousands of longevity clinics at a premium price per infusion but with limited rigorous trial data specifically for the infusion protocol. NAD+ itself isn't a peptide. It's a dinucleotide cofactor, but it lives in the same clinical and commercial space as mitochondrial peptides.

what it is

NAD+ (nicotinamide adenine dinucleotide) is a coenzyme present in every cell, essential for the electron transport chain that produces ATP and a substrate for sirtuins, PARPs, and CD38. structurally a dinucleotide, not a peptide, but commercially clustered with peptides in longevity medicine. discovered in 1906 by Arthur Harden and William Young as 'co-fermentase.'

what it does

powers cellular energy production, supports DNA repair via PARPs, modulates sirtuin-mediated longevity pathways. levels decline roughly 50% from young adulthood to old age, measured across skin, muscle, liver, and blood. supplementation aims to restore those levels. oral precursors (NMN, NR) at 250-1000 mg daily reliably elevate circulating NAD+. IV NAD+ at 250-1000 mg per session is the longevity-clinic format, mostly entering cells after breakdown to nicotinamide.

origin

rediscovered as a longevity target around 2010 through David Sinclair's Harvard lab. the IV protocol traces to 1960s-70s Louisiana addiction medicine (William Hitt) and was repurposed by longevity clinics around 2015-2020. the FDA issued a 2022 letter blocking NMN's dietary-supplement marketing because it was being studied as a drug; that ruling was REVERSED in late 2025 (NPA lawsuit + ANH joint petition). FDA reinstated NMN's dietary-supplement NDI status December 2, 2025, so NMN is again lawful as a supplement.

why researchers are interested

the underlying biology is real and well-documented. NAD+ decline with age is established, oral precursor PK is solid, and modest improvements in insulin sensitivity, muscle function, and aerobic capacity have been reported in randomized trials. the wellness industry built a multi-billion-dollar IV ecosystem around the science.

does it work

yes for raising blood NAD+ via oral precursors. uncertain for everything that comes after. NMN and NR clinical trials show NAD+ elevation and modest metabolic improvements; clear healthspan or lifespan extension in humans has not been demonstrated. IV NAD+ specifically, the format clinics charge $300-1000 a session for, has almost no rigorous controlled trials. A 2026 retrospective tolerability comparison (Frontiers in Aging) found IV NAD+ produced an inflammatory response (white-blood-cell increase) that IV nicotinamide riboside did not. The 2025 MIB-626 trial in COVID/AKI confirmed safe blood NAD+ elevation but no improvement on AKI markers - efficacy null despite biomarker movement. Most positive evidence in this entire space comes from cheaper oral precursor studies, not the IV drip. NAD+ has more real biology than most longevity peptides and still nowhere near the clinical evidence the pricing implies.

claims vs the data

  • NAD+ levels decline with aging in humans — supported — Multiple studies using mass spectrometry in human tissue samples show clear age-related NAD+ decline across skin, muscle, liver, and other tissues. Roughly 50% reduction from young adult levels by age 70-80.
  • oral NMN supplementation raises blood NAD+ levels — supported — Well-documented across multiple human trials. Doses of 250-1000mg daily elevate circulating NAD+ within weeks. Rigorous trial evidence exists for this specific claim.
  • NMN/NR supplementation extends healthspan in humans — weak — Animal models show impressive healthspan effects. Human trials have shown measurable NAD+ elevation and some modest improvements in insulin sensitivity and muscle function, but clear healthspan or lifespan extension in humans has not been demonstrated at any meaningful scale.
  • IV NAD+ infusions cross the cell membrane and raise cellular NAD+ — partially true — NAD+ itself has poor cellular uptake. IV NAD+ primarily enters cells after breakdown to smaller precursors (nicotinamide, others), which are then recycled intracellularly. Some cellular NAD+ elevation does occur but the mechanism is less direct than 'injecting NAD+ puts it in your cells.'
  • IV NAD+ provides clinical benefits beyond oral precursors — weak — Limited rigorous clinical trial data for IV NAD+ specifically. Most published benefits for NAD+ elevation come from oral precursor studies. The premium pricing of IV protocols ($300-1000/session) versus oral supplements is not matched by a proportional evidence advantage.
  • NAD+ precursors improve specific metabolic markers — partially true — Multiple human trials show improvements in insulin sensitivity, muscle mitochondrial function, and some inflammatory markers. Effect sizes are typically modest. The clinical meaningfulness varies by population, more pronounced in older adults and those with metabolic dysfunction.

key facts

  • molecular formula: C21H27N7O14P2
  • molecular weight: 663.4 Da
  • amino acids: n/a (nucleotide, not peptide)
  • half-life: IV: rapid cellular uptake; oral precursors (NMN, NR): hours; endogenous NAD+ cycling: minutes to hours depending on tissue
  • type: dinucleotide cofactor (not a peptide)
  • CAS: 53-84-9
  • 1906 discovered as 'co-fermentase'
  • ~50% NAD+ decline from youth to old age
  • $300-1000 typical longevity clinic IV infusion cost
  • 0 FDA approvals for IV NAD+ in aging

frequently asked questions

What is NAD+?

NAD+ (nicotinamide adenine dinucleotide) is an essential coenzyme found in every cell of the body, central to mitochondrial energy production, DNA repair, and cellular signaling. Technically a nucleotide rather than a peptide, but commonly grouped with peptides in wellness and research chemical markets.

What does NAD+ do?

NAD+ powers cellular energy production (via NADH/NAD+ cycling in the electron transport chain), supports DNA repair enzymes (PARPs), and modulates sirtuin-mediated longevity pathways. Supplemental NAD+ aims to restore levels that decline with age. Clinical evidence is strongest for specific deficiency states; general anti-aging claims have weaker support.

How is NAD+ typically administered?

Intravenous infusion (90-minute drip) is the route wellness clinics most often sell, with reported per-session amounts in the 250-1000mg range. There is no FDA-approved NAD+ dosing for any of these uses; oral precursors (NMN, NR) carry most of the actual evidence. Oral NAD+ itself is largely ineffective.

What are the side effects of NAD+?

IV NAD+ commonly causes chest tightness, flushing, and nausea during infusion (managed by slowing infusion rate). Subcutaneous administration causes injection-site reactions. Long-term supraphysiological NAD+ levels have theoretical concerns regarding tumor support (since NAD+ supports all cell proliferation, including malignant).

Is NAD+ FDA approved?

No. NAD+ has no FDA drug approval for any indication. NAD and NADH appear in FDA's April 22, 2026 503A category 1 list, which reflects interim compounding review status, not therapeutic approval. NMN and NR precursors have more formal supplement and clinical-development histories but also remain without FDA drug approval.

How much does NAD+ cost?

IV NAD+ infusions from wellness clinics are sold per session, often in packages, and are the priciest route. Subcutaneous NAD+ prescribed by clinics is sold as a monthly package. On the research-chemical market it is far cheaper than the clinic routes.

related peptides

  • mots-c — mitochondrial peptide running a similar longevity thesis
  • ss-31 — FDA-approved mitochondrial peptide, different mechanism, same target
  • ghk-cu — longevity-adjacent, often stacked with NAD+ in protocols

reptides grades the research record and cites the literature behind every call. research reference only; not medical advice.